Cargando…

First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease

AIM: To compare the one-week clinical effects of single doses of dexlansoprazole and esomeprazole on grades A and B erosive esophagitis. METHODS: We enrolled 175 adult patients with gastroesophageal reflux disease (GERD). The patients were randomized in a 1:1 ratio into two sequence groups to define...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Chih-Ming, Kuo, Ming-Te, Hsu, Pin-I, Kuo, Chao-Hung, Tai, Wei-Chen, Yang, Shih-Cheng, Wu, Keng-Liang, Wang, Hsing-Ming, Yao, Chih-Chien, Tsai, Cheng-En, Wang, Yao-Kuang, Wang, Jiunn-Wei, Huang, Chih-Fang, Wu, Deng-Chyang, Chuah, Seng-Kee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743510/
https://www.ncbi.nlm.nih.gov/pubmed/29307999
http://dx.doi.org/10.3748/wjg.v23.i47.8395
_version_ 1783288580632739840
author Liang, Chih-Ming
Kuo, Ming-Te
Hsu, Pin-I
Kuo, Chao-Hung
Tai, Wei-Chen
Yang, Shih-Cheng
Wu, Keng-Liang
Wang, Hsing-Ming
Yao, Chih-Chien
Tsai, Cheng-En
Wang, Yao-Kuang
Wang, Jiunn-Wei
Huang, Chih-Fang
Wu, Deng-Chyang
Chuah, Seng-Kee
author_facet Liang, Chih-Ming
Kuo, Ming-Te
Hsu, Pin-I
Kuo, Chao-Hung
Tai, Wei-Chen
Yang, Shih-Cheng
Wu, Keng-Liang
Wang, Hsing-Ming
Yao, Chih-Chien
Tsai, Cheng-En
Wang, Yao-Kuang
Wang, Jiunn-Wei
Huang, Chih-Fang
Wu, Deng-Chyang
Chuah, Seng-Kee
author_sort Liang, Chih-Ming
collection PubMed
description AIM: To compare the one-week clinical effects of single doses of dexlansoprazole and esomeprazole on grades A and B erosive esophagitis. METHODS: We enrolled 175 adult patients with gastroesophageal reflux disease (GERD). The patients were randomized in a 1:1 ratio into two sequence groups to define the order in which they received single doses of dexlansoprazole (n = 88) and esomeprazole (n = 87) for an intention-to-treat analysis. The primary end-points were the complete symptom resolution (CSR) rates at days 1, 3, and 7 after drug administration. RESULTS: Thirteen patients were lost to follow-up, resulting in 81 patients in each group for the per-protocol analysis. The CSRs for both groups were similar at days 1, 3 and 7. In the subgroup analysis, the female patients achieved higher CSRs in the dexlansoprazole group than in the esomeprazole group at day 3 (38.3% vs 18.4%, P = 0.046). An increasing trend toward a higher CSR was observed in the dexlansoprazole group at day 7 (55.3% vs 36.8%, P = 0.09). In the esomeprazole group, female sex was a negative predictive factor for CSR on post-administration day 1 [OR = -1.249 ± 0.543; 95%CI: 0.287 (0.099-0.832), P = 0.022] and day 3 [OR = -1.254 ± 0.519; 95%CI: 0.285 (0.103-0.789), P = 0.016]. Patients with spicy food eating habits achieved lower CSRs on day 1 [37.3% vs 21.4%, OR = -0.969 ± 0.438; 95%CI: 0.380 (0.161-0.896), P = 0.027]. CONCLUSION: The overall CSR for GERD patients was similar at days 1-7 for both the dexlansoprazole and esomeprazole groups, although a higher incidence of CSR was observed on day 3 in female patients who received a single dose of dexlansoprazole.
format Online
Article
Text
id pubmed-5743510
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-57435102018-01-05 First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease Liang, Chih-Ming Kuo, Ming-Te Hsu, Pin-I Kuo, Chao-Hung Tai, Wei-Chen Yang, Shih-Cheng Wu, Keng-Liang Wang, Hsing-Ming Yao, Chih-Chien Tsai, Cheng-En Wang, Yao-Kuang Wang, Jiunn-Wei Huang, Chih-Fang Wu, Deng-Chyang Chuah, Seng-Kee World J Gastroenterol Clinical Trials Study AIM: To compare the one-week clinical effects of single doses of dexlansoprazole and esomeprazole on grades A and B erosive esophagitis. METHODS: We enrolled 175 adult patients with gastroesophageal reflux disease (GERD). The patients were randomized in a 1:1 ratio into two sequence groups to define the order in which they received single doses of dexlansoprazole (n = 88) and esomeprazole (n = 87) for an intention-to-treat analysis. The primary end-points were the complete symptom resolution (CSR) rates at days 1, 3, and 7 after drug administration. RESULTS: Thirteen patients were lost to follow-up, resulting in 81 patients in each group for the per-protocol analysis. The CSRs for both groups were similar at days 1, 3 and 7. In the subgroup analysis, the female patients achieved higher CSRs in the dexlansoprazole group than in the esomeprazole group at day 3 (38.3% vs 18.4%, P = 0.046). An increasing trend toward a higher CSR was observed in the dexlansoprazole group at day 7 (55.3% vs 36.8%, P = 0.09). In the esomeprazole group, female sex was a negative predictive factor for CSR on post-administration day 1 [OR = -1.249 ± 0.543; 95%CI: 0.287 (0.099-0.832), P = 0.022] and day 3 [OR = -1.254 ± 0.519; 95%CI: 0.285 (0.103-0.789), P = 0.016]. Patients with spicy food eating habits achieved lower CSRs on day 1 [37.3% vs 21.4%, OR = -0.969 ± 0.438; 95%CI: 0.380 (0.161-0.896), P = 0.027]. CONCLUSION: The overall CSR for GERD patients was similar at days 1-7 for both the dexlansoprazole and esomeprazole groups, although a higher incidence of CSR was observed on day 3 in female patients who received a single dose of dexlansoprazole. Baishideng Publishing Group Inc 2017-12-21 2017-12-21 /pmc/articles/PMC5743510/ /pubmed/29307999 http://dx.doi.org/10.3748/wjg.v23.i47.8395 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Clinical Trials Study
Liang, Chih-Ming
Kuo, Ming-Te
Hsu, Pin-I
Kuo, Chao-Hung
Tai, Wei-Chen
Yang, Shih-Cheng
Wu, Keng-Liang
Wang, Hsing-Ming
Yao, Chih-Chien
Tsai, Cheng-En
Wang, Yao-Kuang
Wang, Jiunn-Wei
Huang, Chih-Fang
Wu, Deng-Chyang
Chuah, Seng-Kee
First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease
title First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease
title_full First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease
title_fullStr First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease
title_full_unstemmed First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease
title_short First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease
title_sort first-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades a and b gastroesophageal reflux disease
topic Clinical Trials Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743510/
https://www.ncbi.nlm.nih.gov/pubmed/29307999
http://dx.doi.org/10.3748/wjg.v23.i47.8395
work_keys_str_mv AT liangchihming firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT kuomingte firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT hsupini firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT kuochaohung firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT taiweichen firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT yangshihcheng firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT wukengliang firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT wanghsingming firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT yaochihchien firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT tsaichengen firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT wangyaokuang firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT wangjiunnwei firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT huangchihfang firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT wudengchyang firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT chuahsengkee firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease
AT firstweekclinicalresponsestodexlansoprazole60mgandesomeprazole40mgforthetreatmentofgradesaandbgastroesophagealrefluxdisease